Navigation Links
Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference
Date:3/19/2009

SOUTH SAN FRANCISCO, Calif., March 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference on Thursday, March 26, at 10 a.m. Eastern Time in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

For Further Information:


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Receives Going Concern Qualification
2. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
3. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
4. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
5. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
8. China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores
9. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
10. Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
11. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology: